FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.39
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$27.25

02 Jul
2024

-0.170

OPEN

$27.11

-0.62%

HIGH

$27.34

222,252

LOW

$26.70

TARGET
$23.055 -15.4% downside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 54.2 xxx
DPS (cps) 42.8 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 50.0 xxx
Dividend Yield 1.6% xxx
Div Pay Ratio(%) 78.8% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 26/06 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx21.1
DPS All xxxxxxxxxxxxxxx45.3
Sales/Revenue xxxxxxxxxxxxxxx1,629.7 M
Book Value Per Share xxxxxxxxxxxxxxx276.4
Net Operating Cash Flow xxxxxxxxxxxxxxx398.2 M
Net Profit Margin xxxxxxxxxxxxxxx7.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.56 %
Return on Invested Capital xxxxxxxxxxxxxxx7.12 %
Return on Assets xxxxxxxxxxxxxxx5.92 %
Return on Equity xxxxxxxxxxxxxxx7.56 %
Return on Total Capital xxxxxxxxxxxxxxx19.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx88 M
Long Term Debt xxxxxxxxxxxxxxx85 M
Total Debt xxxxxxxxxxxxxxx173 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx75 M
Price To Book Value xxxxxxxxxxxxxxx8.51

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx314.2 M
Capex % of Sales xxxxxxxxxxxxxxx19.28 %
Cost of Goods Sold xxxxxxxxxxxxxxx647 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx641 M
Research & Development xxxxxxxxxxxxxxx184 M
Investments - Total xxxxxxxxxxxxxxx49 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

30/05/2024

4

Lighten

$23.00

-15.60%

Fisher & Paykel Healthcare's FY24 result was stronger-than-expected by Ord Minnett driven by higher revenue, good cost control and better-than-expected gross margin expansion.

The underlying gross margin increased by 216bps to 61% due to lower freight rates, manufacturing efficiencies and increased pricing, which more than offset inflationary pressures, explains the analyst.

A NZ23.5c final dividend was declared, a 2% rise on FY23.

Management guides to revenues of between NZ$1.9-2bn in FY25.

The target rises to $23 from $22. The Lighten rating is retained on valuation 

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 38.70 cents and EPS of 51.70 cents.
Ord Minnett forecasts a full year FY26 dividend of 47.10 cents and EPS of 63.30 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: Copper, Lithium, Retailers & TechnologyOne

Jun 27 2024 - Rudi's View
2
Rudi’s View: Traditional Value Is A Flawed Narrative

Jun 26 2024 - Rudi's View
3
Next Week At A Glance – 24-28 Jun 2024

Jun 21 2024 - Weekly Reports
4
FNArena Corporate Results Monitor – 07-06-2024

Jun 07 2024 - Australia
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-06-24

Jun 07 2024 - Weekly Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
2
ResMed Silences The Doubters

Apr 29 2024 - Australia
3
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
4
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
5
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
6
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
7
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
8
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
9
ResMed Makes A Comeback

Jan 29 2024 - Australia
10
ResMed: The Recovery Has Begun

Jan 23 2024 - Technicals